List of Excipients in Branded Drug MONTELUKAST SODIUM

Generic Drugs Containing MONTELUKAST SODIUM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	montelukast sodium	0054-0259	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	montelukast sodium	0054-0259	FERRIC OXIDE RED
Hikma Pharmaceuticals USA Inc	montelukast sodium	0054-0259	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in MONTELUKAST SODIUM?

# Of NDCs	Excipient
47	ASPARTAME
8	BUTYLATED HYDROXYANISOLE
24	CARNAUBA WAX

Last updated: August 1, 2026

Montelukast sodium is a mature, generic leukotriene receptor antagonist with limited opportunity for molecule-level exclusivity but meaningful commercial potential in pediatric delivery, taste masking, excipient substitution, fixed-dose combinations, and adherence-focused formulations. The strongest strategies target the 4 mg granule and 4 mg/5 mg chewable segments, where palatability, dose flexibility, excipient tolerability, and ease of administration influence product selection.

Montelukast Sodium Excipient Strategy and Commercial Opportunities

What is the regulatory and commercial status of montelukast sodium?

Montelukast sodium is the active pharmaceutical ingredient in Singulair and generic montelukast products. It is approved for asthma prophylaxis, chronic asthma treatment, exercise-induced bronchoconstriction, and allergic rhinitis. The product is marketed in several oral dosage forms:

Dosage form	Typical strength	Primary patient segment
Film-coated tablet	10 mg	Adults and adolescents
Chewable tablet	4 mg, 5 mg	Pediatric patients and patients with swallowing difficulty
Oral granules	4 mg	Young children, including patients unable to chew tablets

The U.S. Food and Drug Administration approved Singulair under NDA 020829. Montelukast sodium is no longer protected by meaningful U.S. compound exclusivity. Generic products are approved through abbreviated new drug applications, and multiple manufacturers compete across tablet, chewable, and granule formats.

FDA required a boxed warning for serious neuropsychiatric events in 2020. The warning affects promotional positioning and prescriber behavior, particularly in allergic rhinitis, where FDA advises reserving montelukast for patients who do not respond adequately to or cannot tolerate alternative therapies (FDA, 2020).

The commercial market is therefore driven by low manufacturing cost, supply reliability, procurement access, pediatric usability, and formulation differentiation rather than by branded-drug pricing power.

What excipients are used in montelukast sodium products?

The reference product uses different excipient systems for each dosage form. The excipient selection reflects the technical requirements of film coating, chewability, granule dispersibility, taste masking, and dose uniformity.

Montelukast 10 mg film-coated tablets

Typical reference-product excipients include:

• Microcrystalline cellulose
• Lactose monohydrate
• Croscarmellose sodium
• Hydroxypropyl cellulose
• Magnesium stearate
• Hypromellose
• Titanium dioxide
• Red ferric oxide
• Carnauba wax

This composition supports direct compression or a closely related compressed-tablet process, rapid disintegration, mechanical strength, and a stable film coat. Lactose and microcrystalline cellulose provide bulk and compressibility. Croscarmellose sodium promotes tablet breakup. Hydroxypropyl cellulose functions as a binder, while magnesium stearate improves ejection and reduces tooling friction.

Montelukast 4 mg and 5 mg chewable tablets

Reference-product chewable tablets generally use:

• Mannitol
• Microcrystalline cellulose
• Croscarmellose sodium
• Aspartame
• Cherry flavor
• Magnesium stearate
• Colorants, including ferric oxide

Mannitol is commercially important because it provides a cooling mouthfeel and a relatively clean taste profile. Aspartame and flavoring address the bitter taste associated with montelukast. The formulation must balance hardness, friability, chewability, dissolution, and sensory acceptance.

Aspartame creates a labeling issue for patients with phenylketonuria. A reformulated product using sucralose, acesulfame potassium, steviol glycosides, or a reduced-sweetener system could target patients, caregivers, and markets where aspartame-free labeling has commercial value.

Montelukast 4 mg oral granules

The granule format uses a low-excipient system, typically including:

• Mannitol
• Hydroxypropyl cellulose
• Magnesium stearate

The granules are administered directly or mixed with a limited range of soft foods or liquids according to product labeling. The format avoids swallowing a tablet and is suited to young children.

Granule design has a higher commercial value than its simple composition suggests. Dose uniformity at the 4 mg level, low segregation, rapid dispersion, acceptable mouthfeel, and resistance to humidity are critical quality attributes.

What excipient strategy is most effective for montelukast sodium?

A strong excipient strategy should be dosage-form-specific rather than based on a single platform. Montelukast sodium products have different technical priorities across adult tablets, pediatric chewables, and granules.

Product objective	Preferred excipient strategy	Commercial rationale
Low-cost adult tablet	Microcrystalline cellulose, lactose or a lactose-free filler, croscarmellose sodium, magnesium stearate	Supports efficient high-volume manufacture
Lactose-free product	Mannitol, dibasic calcium phosphate, or selected spray-dried polyols	Addresses lactose intolerance and procurement differentiation
Improved pediatric taste	Mannitol, high-intensity sweetener, flavor system, polymeric taste mask	Improves caregiver acceptance and adherence
Aspartame-free chewable	Sucralose, acesulfame potassium, steviol glycosides, or combinations	Removes phenylalanine-related labeling concern
Sugar-free pediatric product	Mannitol, xylitol, isomalt, or erythritol-based system	Supports dental-health and sugar-free positioning
Low-moisture granule	Mannitol or another low-hygroscopic carrier with moisture-control packaging	Improves stability and dose uniformity
ODT or fast-dispersing tablet	Porous filler, crospovidone or croscarmellose sodium, taste-masking layer	Targets swallowing difficulty and rapid administration
Reduced-allergen product	Excipient system excluding lactose, aspartame, selected dyes, and animal-derived materials	Broadens patient and institutional eligibility

The most practical development path is a taste-masked, aspartame-free, sugar-free pediatric formulation with a robust granulation and packaging system. A second opportunity is an adult tablet using a lactose-free or low-excipient composition that simplifies sourcing and supports global registration.

What formulation patents could protect a montelukast product?

Montelukast compound protection has expired in major markets. New patent value would therefore depend on formulation, manufacturing, packaging, or use claims.

Potential claim categories include:

1. Taste-masking systems. Polymer coatings, ion-exchange complexes, lipid barriers, multiparticulate coatings, or pH-dependent release systems could protect a granule or chewable product.

2. Pediatric granules. Claims could cover particle-size distribution, drug loading, granule strength, dispersion time, residual solvent limits, or compatibility with specified foods.

3. Chewable tablets. Patentable features could include a particular sweetener-flavor ratio, hardness range, friability profile, dissolution profile, or compressed chewable matrix.

4. Orally disintegrating tablets. Claims could target disintegration time, porous structure, taste-masking layers, and bioequivalence to immediate-release montelukast.

5. Stability and packaging. Moisture-barrier sachets, desiccant systems, unit-dose packages, and protection against oxidation or polymorphic conversion may support narrower patent claims.

6. Manufacturing processes. Continuous blending, low-shear granulation, spray coating, or controlled drying processes may be protectable when they produce a measurable product property.

A formulation patent must provide more than a routine excipient substitution. For a mature immediate-release drug, patent strength improves when the product demonstrates an unexpected technical effect, such as materially improved stability, taste acceptance, dissolution performance, dose uniformity, or reduced manufacturing variability.

How does FDA approval affect montelukast excipient commercialization?

Most conventional generic products use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. The excipients may differ from the reference product if the finished product meets applicable safety, quality, and performance requirements.

A novel delivery system may require a 505(b)(2) application when the sponsor relies partly on FDA findings for a listed drug but introduces a meaningful change in dosage form, route, formulation, or dosing method. This route may be relevant to:

• Orally disintegrating montelukast
• Novel pediatric granules
• Modified taste-masked systems
• Alternative delivery formats
• Fixed-dose combinations

The principal regulatory risks are excipient safety in children, food-effect differences, altered dissolution, dose dumping or delayed release, and failure to demonstrate bioequivalence. A new excipient can increase development time and regulatory burden. The strongest commercial programs generally use previously approved excipients in established oral dosage forms.

What generic entry risks exist for montelukast sodium?

Generic entry risk is high because the product is orally administered, immediate release, chemically defined, and supported by extensive clinical and regulatory history. The barriers are lower than for biologics, inhaled products, depot injections, or complex combination devices.

The principal risks are commercial rather than legal:

• Price erosion from multiple ANDA holders
• Retail substitution
• Purchasing-contract pressure
• Limited differentiation among 10 mg tablets
• Low reimbursement for unbranded products
• Manufacturing interruptions caused by API or excipient shortages
• Pediatric liability and pharmacovigilance exposure
• Reduced use in allergic rhinitis after the boxed warning

A differentiated pediatric product can reduce direct price competition. Its value depends on whether payers, hospitals, government tenders, or caregivers will pay for improved palatability, excipient exclusions, or packaging convenience.

Which companies compete in the montelukast sodium market?

The competitive field includes Merck, the original Singulair sponsor, and generic manufacturers selling montelukast sodium tablets, chewable tablets, and granules. Generic competition has historically included large multinational and U.S. manufacturers such as Teva, Sandoz, Dr. Reddy's, Lupin, Cipla, Apotex, and other regional suppliers, subject to market-specific product approvals.

Competition should be assessed by dosage form rather than by API alone:

Segment	Competitive intensity	Differentiation potential
10 mg film-coated tablet	Very high	Low
5 mg chewable tablet	High	Moderate
4 mg chewable tablet	High	Moderate to high
4 mg granules	Lower than tablets	High
ODT or novel pediatric form	Limited	High, but higher regulatory burden
Fixed-dose respiratory combination	Product-specific	Potentially high

A company with an established pediatric respiratory portfolio, hospital distribution, or contract-manufacturing capacity has a stronger launch position than a standalone API supplier.

What licensing and partnership opportunities exist?

Licensing opportunities are most credible in four areas:

• A protected taste-masking or granule technology
• A pediatric formulation with clinical or sensory data
• A low-moisture unit-dose packaging platform
• A regional commercialization agreement for approved generic products

API supply alone is less differentiated because montelukast sodium is widely available from qualified manufacturers. A formulation license becomes more valuable when it includes regulatory documentation, comparative dissolution data, stability data, scalable manufacturing, and rights in multiple jurisdictions.

Potential partners include generic pharmaceutical companies, pediatric specialty manufacturers, contract development and manufacturing organizations, and companies with established access to public-sector procurement channels.

How strong is the patent estate for montelukast sodium?

The core patent estate is weak for new-product exclusivity because the principal compound protection and branded-product exclusivity have expired. Commercial protection must come from narrower rights.

IP category	Current strategic value
Montelukast compound patent	Expired in major markets
Original tablet formulation	Limited or expired protection
Pediatric chewable formulation	Potentially relevant only if claim scope remains enforceable
Granule technology	Relevant if claims cover non-obvious technical parameters
Taste-masking technology	Moderate to high if supported by performance data
Packaging and stability	Moderate, usually narrow
Manufacturing process	Moderate if difficult to design around
Method-of-use claims	Limited by generic labeling and boxed-warning considerations

A new formulation patent should be screened for freedom-to-operate against both montelukast-specific patents and platform patents covering taste masking, orally disintegrating tablets, multiparticulates, and pediatric dosage forms.

What is the outlook for commercial opportunities?

The highest-value opportunity is a pediatric product that combines:

• 4 mg dose flexibility
• Sugar-free and aspartame-free composition
• Strong taste masking
• Simple administration without water
• Stable unit-dose packaging
• Comparable or superior dissolution
• Clear labeling for young children
• Reliable global manufacturing

A standard 10 mg tablet remains viable as a volume product but has weak differentiation and high price pressure. A chewable or granule product can command better commercial positioning if it solves a specific adherence or excipient problem.

The commercial case should be built around measurable outcomes: reduced rejection by children, improved caregiver administration, lower excipient-related exclusion, fewer dosing errors, improved shelf stability, or reduced manufacturing cost.

Key Takeaways

• Montelukast sodium is a mature generic drug with minimal molecule-level exclusivity.
• Pediatric chewables and 4 mg granules offer the strongest formulation opportunities.
• Mannitol, cellulose derivatives, superdisintegrants, sweeteners, flavors, and moisture-control systems are the principal excipient levers.
• Aspartame-free, sugar-free, lactose-free, and taste-masked products can create practical differentiation.
• Conventional ANDA products face high generic competition and rapid price erosion.
• Novel delivery systems may qualify for a 505(b)(2) pathway but carry greater regulatory and clinical risk.
• New patent value is most likely in taste masking, granule engineering, packaging, stability, and manufacturing processes.
• No biosimilar pathway applies because montelukast sodium is a small-molecule drug.
• FDA's boxed warning limits promotional use in allergic rhinitis and increases the importance of risk-compliant labeling.
• The best licensing targets combine formulation IP with regulatory data and scalable manufacturing.

FAQs

Is montelukast sodium suitable for a new orally disintegrating tablet?

Yes. An orally disintegrating tablet could target pediatric and dysphagic patients, but taste masking, rapid dissolution, mechanical strength, and bioequivalence would determine feasibility.

Can a company patent an aspartame-free montelukast chewable tablet?

An aspartame-free composition alone may be difficult to patent because excipient substitution can be considered routine. Patent strength would improve if the formulation produces unexpected taste, stability, compression, or dissolution results.

Which montelukast dosage form has the lowest competitive pressure?

The 4 mg granule segment generally has less competition than the 10 mg tablet market because it requires pediatric formulation expertise, dose-uniformity control, specialized packaging, and stronger palatability performance.

Does montelukast sodium have biosimilar competition?

No. Montelukast sodium is a chemically synthesized small molecule. Competing products are generics approved primarily through the ANDA pathway, not biosimilars approved under the biologics framework.

Can excipient innovation support premium pricing for generic montelukast?

It can support premium positioning when the product solves a documented problem, such as poor taste, phenylalanine labeling, lactose intolerance, administration without water, or moisture-related stability. A conventional excipient change without clinical or performance differentiation is unlikely to sustain a premium.

References

1. U.S. Food and Drug Administration. (2020). FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. https://www.fda.gov

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, Singulair (montelukast sodium), NDA 020829. https://www.accessdata.fda.gov/scripts/cder/daf/

3. Merck Sharp & Dohme LLC. (2024). Singulair prescribing information. U.S. Food and Drug Administration.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin. U.S. Department of Health and Human Services.